Ken Griffin’s MIRA Pharmaceuticals MIRA Stock Holding History

Ken Griffin’s Portfolio MIRA Stock Details MIRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-97,976	Closed	-$112K	–	15166
2024 Q4	$112K	Buy	+97,976	New	+$128K	﹤0.01%	11303
2024 Q3	–	Sell	-24,396	Closed	-$16.1K	–	14848
2024 Q2	$16.1K	Buy	+24,396	New	+$20K	﹤0.01%	12801

Other funds holding MIRA

CSI

Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JWCA

J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

FAB

First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return

PWM

Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return

Ken Griffin's MIRA Position: Q1 2025 in Review

Ken Griffin sold out of MIRA Pharmaceuticals (MIRA) in Q1 2025, closing a stake of 97,976 shares — an estimated $112K sold.

Ken Griffin first reported a position in MIRA in Q2 2024 and held it in 2 quarters. The position peaked at $112K in Q4 2024. 19 funds tracked by Wall St. Rank hold MIRA as of Q1 2025.

Ken Griffin reported no remaining MIRA Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Ken Griffin sold 97,976 MIRA Pharmaceuticals shares in Q1 2025, an estimated $112K.
Ken Griffin first reported a position in MIRA Pharmaceuticals in Q2 2024 and held it in 2 quarters.
Ken Griffin's MIRA Pharmaceuticals position peaked at $112K in Q4 2024.
19 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.